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1. Abstract 
 Non-Alcoholic Fatty Liver Disease (NAFLD), also known as Hepatic Steatosis, 
affects 30% adults and 5-10% of children in US. Currently, there is no effective treatment 
available for NAFLD. With high-unmet need in a very large and growing population, the 
disorder is a major health burden. Protein Arginine Methyltransferase 5 (PRMT5) is an 
enzyme that adds an additional methyl- group to proteins including histones therefore 
regulating gene expression on transcriptional and post-translational levels. It is known to 
play a significant role in regulating adipogenic gene expression and consequently is 
involved in adipogenesis. PRMT5 has been shown to methylate Sterol Regulatory 
Binding Protein 1a (SREBP-1a) on R321a which stabilizes the protein, increasing its 
transcriptional activity and promoting de novo lipogenesis. However, the role of PRMT5 
in NAFLD has not been dissected. In this study, PRMT5’s regulation of SREBP1 
expression in hepatocytes was investigated. Depleting PRMT5 expression by shRNA 
mediated gene silencing or inhibiting its enzymatic activity by a small molecule inhibitor 
decreased SREBP1 expression both on mRNA and protein levels. However, there is no 
change on its direct target genes involved in de novo lipogenesis. On the contrary, 
PRMT5 knockdown or inhibition markedly reduced the Phosphatidylinositol (PI3K)-
Protein Kinase B (AKT) signaling pathway, in which the expression of genes involved in 
mitochondrial biogenesis was significantly enhanced. As a consequence of PRMT5 
inhibition, lipid droplet accumulation was decreased in the presence of a PRMT5 
inhibitor. The results indicate that PRMT 5 regulates hepatic lipid homeostasis 
independent of SREBP1, and that PRMT5 inhibitor, which is currently in clinical trial for 
cancer treatment, could have beneficial effects on NAFLD. 
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2. Background 
 
Obesity and fatty liver are both conditions characteristic of metabolic syndrome, 
an increasingly threatening health problem throughout the world (18). 36.5% of adults in 
the United States alone have obesity, and as a result are at significant risk for life 
threatening conditions including cardiovascular disease, type II diabetes, and certain 
types of cancer. Obesity is identified using Body Mass Index (BMI), which defines a 
healthy weight for an individual given his/her height. BMI has been shown to correlate 
with an individual’s overall body fat content (1,3). Increased amounts of body fat 
(adipose tissue) and circulating dietary fatty acids, seen in individuals with obesity, can 
have a negative impact on overall health.  
When dietary fatty acids such as palmitic acid or oleic acid are consumed, they 
form triglycerides and lipid droplets that are stored in adipose tissue as a source of energy 
and heat (25). Triglycerides can also travel to the muscles or liver to be oxidized for 
energy. Non-esterified fatty acid (NEFA or free fatty acid) can also be dispensed from 
peripheral adipose tissue and delivered to non-adipose tissue (4,11). In obesity, increased 
amounts of fatty acids and triglycerides causes the ectopic formation of lipid droplets in 
non-adipose tissue, particularly the liver (24,25). The accumulation of ectopic lipids in 
the liver can cause lipotoxicity in hepatocytes. Lipotoxicity is a major contributor to 
several pathological conditions including insulin resistance and hepatic steatosis (24).  
Hepatic steatosis, also known as nonalcoholic fatty liver disease (NAFLD), is 
characterized by lipid accumulation in the liver without history of alcohol abuse (5). 
NAFLD has been investigated in human and animal models in its relation to diet (5,7,26). 
A high-fat diet promoted the development of fatty liver in subjects (7,26). A low-
fat/high-carbohydrate diet also enhanced the development of fatty liver specifically by 
increasing de novo fatty acid synthesis (5). Increased amounts of dietary fat have not only 
been shown to correlate with obesity but also insulin resistance. This results in decreased 
lipolysis by insulin and increased NEFA delivery to the liver (16,17).  
Anomalous lipid metabolism accompanies the activation of the 
Phosphatidylinositol (PI3K)-Protein Kinase B (AKT), mammalian target of rapamycin 
(mTOR) pathway (12). PI3K, a lipid kinase, generates the lipid second messenger 
phosphatidylinositol-3,4,5-triphosphate (PIP3) (13). AKT is recruited to the cell 
membrane in response to the accumulation of PIP3. AKT is then phosphorylated and thus 
activated by phosphoinositide-dependent kinase (PDK) 1 and 2. The activation of AKT 
regulates mTOR (a downstream effector), and as a result, regulates protein synthesis and 
cell growth. Impaired induction of transcription factors such as Carnitine 
palmitoyltransferase (CPT1) and peroxisome proliferator activated receptor (PPAR), is 
associated with inhibition of the mTOR pathway. The mTOR-raptor complex plays a role 
in the signaling of downstream effector S6 kinase 1 (S6K1) which ultimately controls the 
activation of translation and ribosome biosynthesis (6,13).  
Secretion and degradation of Apolipoprotein B (ApoB) along with the gene 
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expression of hepatic Microsomal triglyceride transfer protein (MTTP) are regulated by 
the inhibition of the PI3K-AKT pathway which can result in the negation of insulin-
induced suppression of very low density lipoprotein (VLDL). VLDLs are the largest type 
of lipoprotein responsible for transporting cholesterol and fat in the blood. The PI3K-
AKT-mTOR signaling pathway plays a central role in regulating several pathways 
including de novo lipid biosynthesis, fatty acid oxidation, and VLDL assembly and 
secretion (13). 
There is evidence that activation of PI3K-AKT results in increased expression of 
sterol regulatory binding proteins (SREBPs) as well as its downstream target genes such 
as fatty acid synthases (FASN) (13). SREBPs are transcription factors responsible for the 
stimulation of genes involved in fatty acid and cholesterol synthesis.  The expression of 
SREBPs is inhibited through the regulation of the PI3K/AKT/mTOR pathway (28). 
SREBPs -1a and 1c are primarily involved in fatty acid, triglyceride, and phospholipid 
synthesis whereas SREBP2 is involved in cholesterol synthesis (18, 14). Dysregulation of 
SREBP-1c has been implicated in the pathogenesis of hepatic steatosis, 
hypertriglyceridemia, and insulin resistance (18).  
Protein Arginine Methyltransferase 5 (PRMT5) is a type II PRMT enzyme 
responsible for the post-translational methylation of arginine: monomethylarginine 
(MMA) to symmetric w-NG,N’G-dimethylargine (sDMA). PRMT5 exhibits universal 
expression and has been found in all eukaryotes previously investigated (8). PRMT5 in 
conjunction with methylosome protein 50 (MEP50) is crucial in the splicing of mRNA in 
that it methylates spiceosomal proteins. A previous study of PRMT5 showed that PRMT5 
is needed for correct splicing and, without it, there is selective retention of introns and 
omission of exons with weak 5′ donor sites (8). PRMT5 symmetrically dimethylates 
histones H2AR3, H4R3, H3R2, and H3R8. These are associated with various regulatory 
events in transcription. In general, the modification of histone tails has been shown to be 
a major factor in the epigenetic regulation of gene transcription. PRMT5 catalyzed 
symmetric dimethylarginine also plays an important part in activating or suppressing 
apoptosis (23). PRMT5 has been shown to be necessary in the activation of adipogenic 
gene expression and, consequently, in the regulation of adipogenesis (8,20). PRMT5 
promotes PPARγ2, an adipogenic master transcriptional factor, which exhibits expression 
during pre-adipocyte differentiation (8,9). PRMT5 was shown to methylate SREBP1a on 
R321, increasing the transcriptional activity of SREBP1a in liver cancer cells (14). This 
results in the promotion of de novo lipogenesis (14). Although PRMT5 has certain 
involvement in lipid homeostasis, little is known about the role PRMT5 plays in NAFLD. 
In this study, the role of PRMT5 in NAFLD was investigated in a diet-induced 
obese mouse model. Changes in transcription and expression of genes as well as lipid 
accumulation in a non-transformed mouse liver cell line were analyzed and quantified in 
the presence of PRMT5 inhibitor or shRNA mediated gene knockdown. Through 
analyzing the protein expression or phosphorylation of 70 key proteins involved in more 
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than 20 signaling pathways, it was found that silencing PRMT5 decreases PI3K/AKT 
signaling. The expression of key genes in lipid metabolism was examined by RT-qPCR 
and western blot. Results showed that reducing PRMT5 levels by shRNA or inhibiting its 
enzymatic activity by a small molecule inhibitor decreases phorspho-Akt Thr 308 and 
Ser473. Although PRMT5 depletion decreased the expression of SREBP1, there is no 
change in the expression of its downstream targets ACC and FASN. Instead, inhibiting 
PRMT5 elevates the expression of master transcription factor PPARα and PGC-1α in 
fatty acid β-oxidation and mitochondrial biogenesis. As a consequence of increasing fatty 
acid β-oxidation, cells treated with PRMT5 inhibitor have less lipid droplet accumulation 
when cultured with media containing fatty acids. These results indicate that PRMT5 
regulates hepatic lipid homeostasis independent of SREBP1.  
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3. Materials and Methods 
 
3.1 Cell culture 
AML12 Cells 
Non-transformed alpha mouse liver 12 (AML12) cells were cultured in DMEM/F12 
medium (Invitrogen, San Diego, CA, USA) supplemented with 10% fetal bovine serum 
(FBS) (Sigma-Aldrich, St. Louis, MO), 100 µg/ml streptomysin, and ITS (Invitrogen). 
These cells were grown in monolayers until 80-90% confluency. When splitting the cells, 
media was aspirated from plate/dish and DPBS was added to wash the cells. DPBS was 
then aspirated and 0.05% Trypsin was added (1mL/10cm dish or 0.5mL/well in 6-well 
plate). This was allowed to incubate at 37°C for 3-5 minutes (depending on confluency). 
Media was then added to the plate to neutralize the trypsin. The cells were dislodged 
from the plate by pipetting, transferred to tubes and collected by centrifugation. If cells 
were over confluent, 20 µl of AccumaxTM Cell Counting Solution in DPBS was added to 
each sample and mixed well. This incubated for 10 minutes at room temperature. Cell 
concentration was determined using Cellometer cell counter.  
HEK293T Cells 
HEK293T cells were cultured in DMEM medium (Invitrogen) with 10% FBS and 100 
µg/ml streptomysin. The day before transfect, the cells were cultured in DMEM medium 
with 10% heat inactivated FBS and 100 µg/ml streptomysin.  
 
3.2 Lentiviral shRNA Construction and Transduction 
Prmt5 shRNA knockdown lentiviral constructs were prepared using psp-108 vector 
(Addgene), and the lentivirus cDNAs were produced by co-transfecting with plasmids 
pMD2.G (Addgene) and psPAX2 (Addgene) into HEK293T cells. Titers were 
determined and the same number of virus was used, as indicated. Prmt5 knockdown 
targeting sequences are: shRNA1 5’GCACAGTTTGAGATGCCTTAT3’; shRNA2, 
5’CCTCTTGTGAATGCGTCTCTT3’.. 
 
3.3 Cell Proliferation Assay 
 
Inhibitor Treatment 
Initial Treatment Method 
AML12 cells were plated in a 96-well plate at 3000 cells/well. These were allowed to 
incubate at 37°C overnight. Cells were then treated with EPZ molecular inhibitor at 
25nM, 50nM, 100nM, 250nM, and 500nM using 0.05% DMSO as a control. The cells 
were allowed to incubate with the inhibitor treatment for 11 days.  
Secondary Treatment Method 
Cells were treated with EPZ molecular inhibitor at 25nM, 50nM, 100nM, 250nM, and 
500nM using 0.05% DMSO as a control. The cells were allowed to incubate with the 
	 8	
inhibitor treatment for 11 days (passaged on day 5). On day 11, treated cells were plated 
in 2 96-well plates: 5000 cells/well in Plate 1 and 3000 cells/well in Plate 2. These plates 
were allowed to incubate for six days at 37°C. Below shows plating and inhibitor 
treatment. 
Below shows plating and treatment for Initial and Secondary Methods. 
 
Figure 1: AML12 cell plating and EPZ015666 treatment in a 96-well plate. Gray wells (Rows A and H and 
columns 1 and 12) did not contain cells and instead only contained media or PBS in order to help prevent 
contamination. White wells (row B) were treated with 0.05% DMSO control. Blue wells were treated with 
increasing concentrations of EPZ015666 inhibitor. Row C was treated with 25nM, Row D was treated with 
50nM, Row E was treated with 100nM, Row F was treated with 250nM and row G was treated with 500nM 
EPZ015666.    
 
 
MTT Assay 
Following inhibitor treatment, 10 µl of 5 mg/mL MTT reagent was added to each well 
containing cells and the plate was returned to incubator for at least 4 hours. After 
incubation the media was removed. The plates were then inverted and allowed to dry 
overnight. 100 µl of DMSO was added to each well containing cells and plates were put 
on a shaker for 1 hour at room temperature with gentle shaking. Absorbance at OD540 
was then determined using the Synergy HT Multi-Detection Microplate Reader. 
 
3.4 RT- qPCR 
 
EPZ015666 Treated AML12 Cells 
AML12 cells were plated in 6-well plates at approximately 250,000 cells/well. Cells were 
treated with PRMT5 inhibitor EPZ015666 at 25nM, 50nM, 100nM, 250nM, and 500nM 
using 0.05% DMSO as a control (approximately 24 hours after initial plating). The cells 
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were incubated continuously with the inhibitor treatment for 14 days (passaged 2, 5, and 
11 days from treatment). 
 
RNA extraction  
 Following 14 days of inhibitor treatment or transduction of sh-RNA, media was removed 
from the plate and 0.5 mL TRIzol Reagent was added to each well. The plate was stored 
at -80 °C overnight. Total RNA was isolated using Direct-zol RNA MiniPrep kit. The 
plate was then allowed to thaw at room temperature. After thawing, samples were 
transferred from the plate to 1.5 mL eppendorf tubes and centrifuged for 10 minutes at 
10,000 rpm. Supernatants were then transferred to new eppendorf tubes. Samples 
containing sh-RNA were not centrifuged and entire samples instead of just supernatants 
were used for following step. 0.5 mL of 100% ethanol was added and mixed thoroughly. 
The samples were then transferred to Zymo-Spin IIC Columns and centrifuged at 
13,000rpm for 30 seconds. After removal of the flowthrough, 400 µl of RNA wash buffer 
was added to each column and centrifuged for 30 seconds at 13,000 rpm. DNA 
contamination was removed by on column DNase I digestion. A mixture of DNase I and 
DNA Digestion buffer was added directly to the column matrix (5 µl DNase and 75 µl of 
DNA Digestion buffer per sample) and incubated at room temperature for 15 minutes. 
After incubation, 400 µl RNA Pre-Wash was added to each sample column and 
centrifuged for 30 seconds at 13,000 rpm. After	flow-through	was	discarded,	this	step	was	repeated.	700	µl	RNA	Wash	Buffer	was	then	added	to	the	column	and	centrifuged	for	2	minutes	to	ensure	complete	removal	of	the	wash	buffer.	The 
column was then transferred to a clean tube and RNA was eluted using 50 µl of 
DNAse/RNase free water. RNA concentration was quantified by nanodrop. RNA samples 
were stored until use at -80°C. 
 
Reverse Transcription (cDNA synthesis) 
A total volume of 11 µl RNA extracted from AML12 cells was added to each tube 
(diluted with distilled water based on concentrations). 1 µl of random hexamers and 1 µl 
of 10 mM dNTP were also added. The mixture was heated at 65°C for 5 minutes on a 
thermocycler PCR then immediately placed on ice. The samples were centrifuged briefly. 
A mixture of 4 µl 5X First Strand Buffer, 1 µl 0.1M DTT, 1 µl RNAse inhibitor, and 1 µl 
SuperScript III reverse transcriptase was then added to each sample and mixed well. The 
samples were incubated at 50°C for 30 minutes then at 70°C for 15 minutes in a 
thermocycler PCR.  
 
Real time quantitative PCR 
10 µl of 2X SYBR Green Mastermix, 1 µl of sample cDNA, 2 µl of primer mix, and 7 µl 
of distilled water were added to each well in a 96-well qPCR plate. The plate was sealed 
with MicroAmp Optical Adhesive Film and centrifuged briefly. The real time 
quantitative PCR was run in ABI StepOne PCR machine. Gene expression was calculated 
using the ΔΔCT method. Below shows cDNA and primer plating. 
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Figure 2: RT-qPCR plating for PRMT5 sh-RNA1 treated AML12 cells. Rows A-D contain total cDNA 
from untreated AML12 cells. Rows E-H contain total cDNA from sh-RNA treated cells. Column 1 contains 
UA56 primers (housekeeping gene target), 2 contains ACC primers, 3 contains FASN primers, 4 contains 
LXR primers, 5 contains CPT1 primers, 6 contains PPARα primers, 7 contains PPARγ primers, 8 contains 
ApoB primers, 9 containts FOX1 primers, 10 contains MTTP1 primers, 11 contains Cidea primers, and 12 
contains UCP1 primers.  
 
 
Figure 3: RT-qPCR plating for EPZ015666 treated AML12 Cells. White wells (columns 1 and 2) contain 
total cDNA from AML12 cells treated with 0.05% DMSO. Blue wells contain total cDNA from AML12 
cells treated with  EPZ015666 at 25nM (columns 3 and 4), 50nM (columns 5 and 6), 100nM (columns 7 
and 8), 250nM (columns 9 and 10), and 500nM (columns 11 and 12). Rows A and B contain U36 Primers 
(Housekeeping gene target), Rows C and D contain SREBP1 Primers, Rows E and F contain ACC primers, 
and rows G and H contain FASN primers.  
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3.5 Western Blot 
 
 
Materials 
Cell Lysis Buffer: 
Lysis buffer was prepared using 150mM NaCl, 50 mM Tris-HCl pH 7.5, 1% Triton-
X100, and 5% Glycerol. 
Polyacrylamide Gel: 
8% resolving gel was prepared using distilled water, BIO RAD 30% Acrylamide/Bis 
Solution 29:1, Tris-HCl pH 8.8, 10% SDS, AP, and BIO RAD TEMED. Casting frame 
was set using 1.5 mm spacing plates and liquid gel was added and leveled using 100% 
ethanol. After allowing the gel to polymerize for 30 minutes at room temperature, the 
ethanol was disposed of and the gel was rinsed with distilled water. 5% stacking gel was 
prepared using distilled water, BIO RAD 30% Acrylamide/Bis Solution 29:1, Tris-HCl 
pH 6.8, 10% SDS, AP, and BIO RAD TEMED. Stacking gel was added on top of the 
resolving layer and well combs were immediately placed in the stacking layer. After 
polymerizing for 30 minutes, gels were placed in plastic wrap with 1X PBS and stored at 
4°C until use. 
Loading Buffer: 
1X Loading buffer was made using 1M Tris HCl pH 6.8, 10% SDS, Glycerol, B-
mercaptoethanol, 1% Bromophonol blue, and distilled water.  
Running Buffer: 
1X Running Buffer was prepared using Glycine, Tris base, 10% SDS, and distilled water. 
Transfer Buffer: 
1X Transfer Buffer was prepared using Glycine, Tris base, Methanol, and distilled water 
 
Inhibitor Treatment 
AML12 cells were plated in 6-well plates at approximately 250,000 cells/well. Cells were 
treated with PRMT5 inhibitor EPZ015666 at 25nM, 50nM, 100nM, 250nM, and 500nM 
using 0.05% DMSO as a control (approximately 24 hours after initial plating). The cells 
were incubated continuously with the inhibitor treatment for 14 days (passaged 2, 5, and 
11 days from treatment). 
 
Protein Extraction 
Initial Method 
After 14 days of inhibitor treatment, media was removed from 6-well plates and cells 
were rinsed with PBS. PBS was aspirated and cells were stored at -80°C until use. Cells 
were allowed to thaw at room temperature. 150 µl of Lysis buffer was added to each well 
and cells were transferred to tubes. Tubes were centrifuged at 13,200 rpm for 10 minutes 
at 4°C. Following centrifugation, supernatants containing total proteins were transferred 
to separate tubes. Protein concentration was measured using Bradford Method. 100 µl of 
each supernatant was transferred to separate tubes and 25 µl of loading buffer was added 
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to each tube. Tubes were placed in a heat block and boiled at 100°C for 10 minutes. 
Protein samples were stored at -80°C until use. 
Optimized Method 
Following secondary inhibitor treatment method, cells were scraped from 6-well plates 
and transferred to separate tubes containing media. Cells were counted using Cellometer 
cell counter and transferred to separate tubes at one million cells per tube. The cells were 
then pelleted and stored at -80°C until use. Cells were briefly allowed to thaw then 100 µl 
of loading buffer was added to each tube and briefly mixed with a pipette. Tubes were 
then heated at 95°C for 10 minutes. 
 
Electrophoresis and Blotting 
Gels were placed in Xcell SureLock Mini-Cell according to instructions. 1X running 
buffer was added and samples were loaded into wells based on previously determined 
concentration from Bradford assay. 
10 µl of Invitrogen BenchmarkTM Prestained Protein Ladder was added for reference . 
Gels were initial run at 60V for 30 minutes then at 150V for an additional 90 minutes. 
Following Electrophoresis, gels were removed from the glass plates and transferred to 
nitrocellulose membranes in Xcell II Blot Module. 1X transfer buffer was added and the 
module was placed in icebath. This was allowed to run for 1-4 hours at 100V depending 
on the size of desired proteins. 
 
Membrane Blocking 
Non-specific binding sites were blocked by immersing the membrane in 5% non-fat dried 
milk in TBST buffer for 1 hour at room temperature on an orbital shaker.  
 
Primary and Secondary Antibody Incubation 
Primary antibody for specified protein was diluted in TBST buffer containing 5% non-fat 
milk. The membrane was incubated in the primary antibody overnight at 4°C on an 
orbital shaker. Following this, the membrane was rinsed with 2 changes of washing 
buffer (1xPBS containing 0.04% Tween20) then 3 changes of washing buffer for 15 
minutes each. The membrane then incubated in HRP conjugated secondary antibody for 1 
hour at room temperature on an orbital shaker. Following this, the membrane was rinsed 
with 2 changes of wash buffer then 3 changes of wash buffer for 15 minutes each. 
 
Detection 
Enhanced chemiluminescence (ECL) reagent was added to the membrane and briefly 
incubated for 1 minute at room temperature. Then the membrane was placed in plastic 
wrap and taped to the inside of an x-ray film cassette and exposed for several minutes.  
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3.6 Fatty Acid Accumulation Assay 
Inhibitor Treatment 
Cells were treated with EPZ molecular inhibitor at 25nM, 50nM, 100nM, 250nM, and 
500nM using 0.05% DMSO as a control (approximately 24 hours after initial plating). 
The cells were allowed to incubate with the inhibitor treatment for 15 days (passaged 2, 
5, and 11 days from treatment). On day 11 cells were plated in a 24-well plate in 
preparation for fatty acid treatment. 
Fatty acid treatment 
On day 15 of inhibitor treatment, cells in the 24-well plate were treated with 1 µM 
palmitic, 100 µM oleic acid, or in combination using BSA as a control. This was allowed 
to incubate at 37°C for 4 days. Below shows fatty acid and inhibitor treatment.  
 
 
Figure 4: EPZ015666 Inhibitor and Fatty Acid Treatment in a 24-well plate. The top value in each well 
shows the inhibitor treatment concentration using 0.05%DMSO in the first column as a control. The bottom 
value in each well shows fatty acid treatment concentration (using palmitic or oleic acid) with 5% BSA as a 
control.  
 
Oil Red O Staining 
On the fourth day of fatty acid treatment, media was removed from wells and 1 mL of 
Formalin was added to each well. This was allowed to incubate at room temperature for 1 
hour in order to fix the cells. The formalin was then removed and the cells were washed 
twice with distilled water. 1 mL of 60% isopropanol was then added to each well and 
allowed to incubate at room temperature for 5 minutes. The isopropanol was then 
removed and 1 mL of Oil Red O solution was added to each well. The plate was covered 
with aluminum foil and allowed to incubate overnight on a shaker at room temperature.  
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3.7 Mitochondrial Staining 
Cells were seeded on glass cover slips and incubated overnight. For mitochondria 
staining, cells were incubated with MitotrackerTM Red CMXRos (250nM, ThermoFish, 
cat#M7512) at 37oC for 30 minutes, before being fixed with 4% paraformaldehyde for 20 
min at room temperature, followed by permeabilization in ice-cold methanol for 10 min 
at –20°C. Cells were then incubated in blocking buffer (5% bovine serum albumin in 
PBS) for 1 hour at room temperature followed by incubation with anti-PRMT5 antibody 
(Santa Cruz Biotechnology, cat# sc-376937) and anti-β-tubulin antibody (Cell Signaling 
Technology, cat# 15115) at 4°C overnight. Cells were washed three times for 5 min in 
PBS, and then incubated for 2 hours with Alexa Fluor 488-conjugated goat anti-mouse 
secondary antibody against PRMT5 and Alexa Fluor 555-conjugated goat anti-rabbit 
secondary antibody for β-tubulin (diluted 1:100 in blocking buffer; Invitrogen) at room 
temperature. Finally, the nuclei were stained with DAPI for 30 min at room temperature 
before visualization. 
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4. Results 
 
4.1 The Effect of EPZ015666 on Liver Cell Proliferation  
Cell proliferation assays were performed in order to determine the impact of EPZ015666 
treatment on cell proliferation of AM12 cells. PRMT5 is overexpressed in breast cancer 
cells as well as epithelial ovarian cancer cells (2,27). This suggests that PRMT5 may 
have a role in abnormal cell proliferation.  PRMT5 has also been shown to be necessary 
for cell proliferation in MCF7 cell lines (22). Below shows the results following 
EPZ015666 treatment and MTT assay. The results show no significant difference in cell 
proliferation between cells treated with EPZ015666 and cells treated with 0.05% DMSO. 
Supplemental MTT assays were also performed after treating AML12 cells with 
EPZ015666 for several months. These results also indicated no significant different 
between cells treated with EPZ015666 and cells treated with DMSO. 
 
Table 1a: Absorbance values from Cell Proliferation Assay (MTT). AML12 cells had been treated with 
EPZ015666 using primary treatment method. 
 
 
Table 1b: Absorbance values from Cell Proliferation Assay (MTT). AML12 cells were originally plated at 
3000 cells/well and treated with EPZ015666 using secondary treatment method.  
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Table 1c: Absorbance values from Cell Proliferation Assay (MTT ). AML12 cells were originally plated at 
5000 cells/well and treated with EPZ015666 using secondary treatment method.  
 
4.2 Gene expression Measured by RT-qPCR 
PRMT5 knockdown by shRNA mediated gene silencing 
Since PRMT5 sh-RNA1 has better efficiency in silencing PRMT5, I used RNA extracted 
from scramble or PRMT5 sh-RNA1 to profile gene expression of key metabolic 
regulators invovlved in hepatic lipid homeostasis. RT-qPCR was performed using total 
cDNA from scramble or PRMT5 sh-RNA1 tranduced AML12 cells in order to determine 
the effect of inhibiting PRMT5 on the fold change of various genes involved in lipid 
metabolism. 
Below shows the gene expression following sh-RNA1 treatment measured by RT-qPCR. 
Results show that the fold change of PPARα is increased significantly compared to the 
housekeeping gene. MTTP and Cidea also show a significant increase.  
 
Table 2: Relative gene expression quantified by RT-qPCR in PRMT5 knockdown cells. An untreated 
(scramble) AML12 cell line was used as a control and UA56 was used as the housekeeping gene. Average 
Fold change was calculated using the ΔΔCT method. 
 
 
Below shows the gene expression of Prmt5, PPARα, and PGC-1α following sh-RNA1 
and sh-RNA2 treatment measured by RT-qPCR. Results show that the fold change of 
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PPARα and PGC-1α is significantly increased when compared to the scramble. The 
Prmt5 fold change indicates that Prmt5 was successfully inhibited by sh-RNA. 
 
Figure 5: PPARα and PGC-1α expression measured by RT-qPCR in PRMT5 knockdown cells. Relative 
mRNA of PPARα and PGC-1α was measured from sh-RNA1 and sh-RNA2 treated AML12 cells using an 
untreated AML12 cell line (scramble) as a control. Prmt5 levels are also shown as a reference. 
 
PRMT5 Molecule Inhibitor 
RT-qPCR was performed using total cDNA from EPZ015666 treated AML12 cells in 
order to determine the effect of EPZ015666 treatment on the fold change of certain genes 
involved in lipid metabolism.  
Below shows the total RNA concentration following extraction. It was found that total 
RNA concentration for 50nM and 500nM treated cells was below 100 ng/µl. At least 
100ng/µl is typically desired for qPCR and the lower concentrations could have affected 
the RT-qPCR results.  
 
Table 3: Total RNA concentrations extracted from AML12 cells treated with EPZ015666. that had been 
treated for 14 days using 0.05% DMSO is used as a control. 
 
 
Below shows the gene expression following EPZ015666 treatment of AML12 cells 
measured by RT-qPCR. Results show that the fold change of SREBP1, ACC, and FASN 
does not increase overall with EPZ015666 treatment. 
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Figure 6: The effect of EPZ015666 treatment on SREBP1, ACC, & FASN expression determined by RT-
qPCR. 0.05% DMSO is used as a control and U36 is used as the housekeeping gene. Average Fold change 
was calculated using the ΔΔCT method. 
 
Below shows the relative gene expression following EPZ015666 treatment measured by 
RT-qPCR. Results show that the fold change for PPARα and PGC-1α increases with 
increased concentration of EPZ015666 treatment. 
 
Figure 7: The effect of EPZ015666 treatment on PPARα and PGC-1α expression determined by RT-qPCR. 
Relative mRNA of PPARα and PGC-1α was measured from EPZ015666 treated AML12 cells (using 
DMSO as a control). 
 
4.3 Protein Levels Determined by Western Blot 
PRMT5 sh-RNA Knockdown 
Western blot was performed following sh-RNA1 and shRNA-2 treatment of AML12 
cells in order to assess the effect of a PRMT5 knockdown on several genes involved in 
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lipid metabolism. Below shows Western blot results following sh-RNA1 and sh-RNA2 
treatment of AML12 cells. Results show that protein expression of PPARα is increased in 
cells treated with sh-RNA when compared to untreated cells (scramble). SREBP1 shows 
a significant decrease in protein expression in sh-RNA treated cells.  
 
Figure 8: Protein levels of SREBP1, PPARα detected by Western blot in PRMT5 knockdown cells. PPARα 
and SREBP1 blots are shown with Tubulin used as a loading control. 
 
Figure 9: Protein levels of p-mTOR Ser2448, Total-mTOR, FASN, ACC & MTTP detected by Western 
Blot in PRMT5 knockdown cells. Tubulin was used as a loading control. 
 
Western Blot was performed following EPZ015666 inhibitor treatment in order to 
determine the effect of Prmt5 inhibition using a molecule inhibitor on protein expression 
of several genes involved in lipid metabolism.  
Below shows protein concentrations following initial protein extraction from cells treated 
with EPZ015666.  
 
Table 4: Total protein concentration measured by Bradford method in EPZ015666 treated cells. Cells were 
treated with EPZ015666 for 14 days using 0.05% DMSO as a control. 
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Below shows Western Blot results from an additional EPZ015666 inhibitor treatment and 
total protein extraction from AML12 cells. Results show that protein expression for p-
AKt-Thr308, p-Akt-Ser473, and SREBP1 is decreased with EPZ015666 inhibitor 
treatment when compared to cells treated with DMSO control. Protein expression of 
PPARα is increased with EPZ015666 inhibitor treatment. 
 
 
Figure 10: Protein levels of p-Akt-Thr308, p-Akt-Ser473, PPARα, & SREBP1 detected by Western Blot in 
EPZ015666 treated cells. DMSO was used as a control and Tubulin was used as a housekeeping gene.  
 
4.4 Intracellular Lipid Accumulation 
Fatty acid accumulation assays were done in order to determine the effect of EPZ015666 
treatment on lipid formation after cells were treated with fatty acids. 
Results are not given from original treatment method because Oil Red O Staining was 
unsuccessful. It is possible that the cells were too confluent when they were originally 
treated with fatty acid. This would have made lipid accumulation difficult and made it 
hard for the staining to take. In the future cells should be treated with fatty acid 
approximately 24 hours after plating.  
Below shows Oil Red O staining from a secondary fatty acid accumulation assay of cells 
treated with DMSO and 100nM EPZ015666. Results show that fatty acid 
accumulation/lipid formation is decreased in cells treated with EPZ015666. 
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Figure 11: Lipid accumulation in EPZ015666 treated cells by Oil Red O Staining. AML 12 cells were 
treated with 100nM EPZ015666 using DMSO as a control. Cells were treated with 10 uM palmitic acid and 
100 uM oleic acid. 
 
4.5 The effect of PRMT5 inhibition of mitochondrial biogenesis 
In PRMT5 knockdown cells 
Mitochondrial staining assays were performed in order to assess the effect of a PRMT5 
sh-RNA knockdown or inhibition by molecule inhibitor EPZ015666 on mitochondrial 
biogenesis.  
Below shows mitochondrial staining following the treatment of AML12 cells with 
PRMT5 sh-RNA. Results show that inhibiting PRMT5 by sh-RNA results in the increase 
of mitochondrial biogenesis. 
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Figure 12: Mitochondrial staining in PRMT5 knockdown cells. The mitochondria were stained with 
mitochondrion selective dye MitotrackerTM Red CMXRos, Prmt5 expression was visualized by 
immunofluorescent staining (green), and nuclei were labeled by DAPI (blue), size bar: 200 µm. Each bar 
presents the mean of 3 independent experiments performed in triplicates; error bars are standard deviations.  
**, p < 0.01, ***p < 0.001, two-tailed Student’s t test. 
 
Mitochondrial staining in EPZ015666 treated cells 
Below shows mitochondrial staining following the treatment of AML12 cells with 
EPZ015666. Results show that inhibiting PRMT5 by molecule inhibitor increases 
mitochondrial biogenesis. 
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Figure 13: Mitochondrial staining in EPZ015666 treated cells. AML12 cells treated with DMSO or 100nM 
EPZ01666 were stained by MitotrackerTM Red CMXRos (red) following DMSO or 100nM EPZ015666 
treatment. Nuclei were labeled by DAPI (blue), size bar: 200 µm. ***p < 0.001, two-tailed Student’s t test. 
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5. Discussion 
The Importance of Investigating PRMT5 
In a study conducted of individuals from 1992-2012, 30% of people in the United States 
were determined to suffer from NAFLD with 10.3% having advanced fibrosis (based on a 
6000 person sample size) (10). NAFLD is a serious and widely prevalent disease, 
especially in the United States, for which successful therapies do not yet exist. For this 
reason, the study of PRMT5 and other genes involved in lipid metabolism in hepatocytes 
is vital to the discovery of possible NAFLD therapies.  
 
PRMT5 inhibition intervenes in lipid homeostasis independent of SREBP1 
This study investigated the involvement of PRMT5 in lipid metabolism in hepatocytes 
and consequently how it functions in the context of NAFLD. It was reported in a previous 
study that PRMT5 methylates SREBP1a on R321 which increases this SREBP’s 
transcriptional activity and therefore promotes de novo lipogenesis.  
The present study revealed that PRMT5 inhibition by a small molecule inhibitor 
intervenes in lipid homeostasis independent of its effect on SREBP1. In particular, 
PRMT5 negatively regulates p-AKT-Thr308 and p-AKT-Ser473 indicating that PRMT5 
has a significant role in the PI3K-AKT pathway. PRMT5 also negatively regulates master 
transcription factors PPARα and PGC-1α.  
PRMT5 inhibition enhances hepatocyte mitochondrial biogenesis 
Specifically the inhibition of Prmt5 by a small molecule inhibitor or sh-RNA increases 
the expression of master regulators of mitochondrial biogenesis PPARα and PGC-1α. Up-
regulation of these genes led to increased mitochondrial biogenesis shown as 
mitochondrial staining in PRMT5 knockdown cells as well as cells treated with 
EPZ015666 (Figures 10 and 11). Increased mitochondrial mass is positively linked to 
enhanced fatty acid oxidation (21) As a consequence of elevated fatty acid oxidation, less 
lipid droplets were accumulated in EPZ015666 treated AML12 cells than in cells treated 
with DMSO cultured in media supplemented with additional dietary fatty acids. Evidence 
of decreased lipid droplets in inhibitor treated cells can be seen in Figure 9. This suggests 
that inhibiting PRMT5 could have a positive effect on NAFLD. 
EPZ015666 has no effect on liver cell proliferation 
Cell proliferation assays consistently showed that there was no overall effect of inhibitor 
treatment on cell proliferation after 11-14 days of treatment. Supplemental results also 
showed no significant effect of EPZ015666 treatment after several months of treatment. 
This result is contradictory to previous studies, which showed that EPZ015666 treatment 
dramatically inhibits cell proliferation in various cancer cells and causes apoptosis. This 
suggests that EPZ015666 has the potential to treat NAFLD in the future without causing 
other health problems related to hepatocyte proliferation.  
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Future study 
In this study, it was seen that PMRT5 knockdown or inhibition by EPZ015666 up-
regulates the expression of PPARα and PGC-1α in liver cells.  However, it is not clear 
whether PPARα and PGC-1α are direct targets of PRMT5 or this regulation is mediated 
by AKT.  Bioinformatic analysis of PRMT5 ChIP-seq datasets in public databases such 
as NCBI GEO may yield information about how PRMT5 binds at PPARα and PGC-1α 
promoters or enhancers together with transcriptional repressive marks such as H3K27. 
Meanwhile, PRMT5 was shown to methylate H3R4 and recruits DNMT3A, which is 
associated with DNA methylation and gene silencing. Therefore, DNA methylation data 
at PPARα and PGC-1α loci may also provide information for the mechanism.  
Alternatively, the regulation of PPARα and PGC-1α could be through the AKT pathway. 
This can be investigated by the expression of activated AKT (myr-AKT) in PRMT5 
knockdown or EPZ015666 treated cells to see if it blocks the up-regulation of PPARα 
and PGC-1α.  These experiments will further address the mechanism by which PRMT5 
regulates mitochondrial biogenesis. 
 
Conclusion 
The present results showed that PRMT5 is an upstream regulator of PI3K/AKT 
signaling. Moreover, PRMT5 negatively regulates the expression of master 
transcription factor PPARα and PGC-1α in mitochondrial biogenesis. These results 
suggest that targeting PRMT5 may have therapeutic value to treat fatty liver. 
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